NEOG vs. QDEL, CLDX, NTLA, MYGN, LNTH, MOR, LFST, BHC, TGTX, and HIMS
Should you be buying Neogen stock or one of its competitors? The main competitors of Neogen include QuidelOrtho (QDEL), Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Lantheus (LNTH), MorphoSys (MOR), LifeStance Health Group (LFST), Bausch Health Companies (BHC), TG Therapeutics (TGTX), and Hims & Hers Health (HIMS). These companies are all part of the "medical" sector.
QuidelOrtho (NASDAQ:QDEL) and Neogen (NASDAQ:NEOG) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, community ranking, valuation, dividends and profitability.
99.0% of QuidelOrtho shares are owned by institutional investors. Comparatively, 96.7% of Neogen shares are owned by institutional investors. 1.0% of QuidelOrtho shares are owned by company insiders. Comparatively, 0.7% of Neogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, QuidelOrtho had 13 more articles in the media than Neogen. MarketBeat recorded 17 mentions for QuidelOrtho and 4 mentions for Neogen. QuidelOrtho's average media sentiment score of 0.36 beat Neogen's score of 0.10 indicating that Neogen is being referred to more favorably in the news media.
QuidelOrtho has higher revenue and earnings than Neogen. QuidelOrtho is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.
Neogen has a net margin of 0.17% compared to Neogen's net margin of -61.65%. Neogen's return on equity of 3.96% beat QuidelOrtho's return on equity.
QuidelOrtho currently has a consensus target price of $59.00, indicating a potential upside of 38.47%. Neogen has a consensus target price of $22.50, indicating a potential upside of 82.48%. Given QuidelOrtho's stronger consensus rating and higher probable upside, analysts plainly believe Neogen is more favorable than QuidelOrtho.
QuidelOrtho has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, Neogen has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.
QuidelOrtho received 110 more outperform votes than Neogen when rated by MarketBeat users. Likewise, 67.28% of users gave QuidelOrtho an outperform vote while only 57.19% of users gave Neogen an outperform vote.
Summary
QuidelOrtho and Neogen tied by winning 9 of the 18 factors compared between the two stocks.
Get Neogen News Delivered to You Automatically
Sign up to receive the latest news and ratings for NEOG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NEOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
